ZA200710551B - Use of sanglifehrin in HCV - Google Patents

Use of sanglifehrin in HCV

Info

Publication number
ZA200710551B
ZA200710551B ZA200710551A ZA200710551A ZA200710551B ZA 200710551 B ZA200710551 B ZA 200710551B ZA 200710551 A ZA200710551 A ZA 200710551A ZA 200710551 A ZA200710551 A ZA 200710551A ZA 200710551 B ZA200710551 B ZA 200710551B
Authority
ZA
South Africa
Prior art keywords
sanglifehrin
hcv
Prior art date
Application number
ZA200710551A
Other languages
English (en)
Inventor
Lin Kai
Weidmann Beat
Zimmermann Kaspar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200710551(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200710551B publication Critical patent/ZA200710551B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200710551A 2005-06-17 2007-12-04 Use of sanglifehrin in HCV ZA200710551B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69149705P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ZA200710551B true ZA200710551B (en) 2008-11-26

Family

ID=37075234

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710551A ZA200710551B (en) 2005-06-17 2007-12-04 Use of sanglifehrin in HCV

Country Status (21)

Country Link
US (1) US20090221598A1 (de)
EP (1) EP1893211B1 (de)
JP (1) JP2008546708A (de)
KR (1) KR20080033274A (de)
CN (1) CN101242842A (de)
AR (1) AR054778A1 (de)
AT (1) ATE524183T1 (de)
AU (1) AU2006259348B2 (de)
BR (1) BRPI0613142A2 (de)
CA (1) CA2611151A1 (de)
EC (1) ECSP078029A (de)
GT (1) GT200600262A (de)
MA (1) MA29600B1 (de)
MX (1) MX2007016068A (de)
NO (1) NO20080351L (de)
PE (1) PE20070118A1 (de)
RU (1) RU2427372C2 (de)
TN (1) TNSN07477A1 (de)
TW (1) TW200740438A (de)
WO (1) WO2006138507A1 (de)
ZA (1) ZA200710551B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2342335B1 (de) * 2008-09-24 2015-09-16 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Neuer gencluster
US20120295346A1 (en) * 2009-07-22 2012-11-22 Tufts University Methods and compositions for modulating membrane potential to influence cell behavior
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
AU2011214135B2 (en) 2010-02-09 2014-07-31 Neurovive Pharmaceutical Ab Sanglifehrin based compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
UY33775A (es) * 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
BR112013015501A2 (pt) * 2010-12-20 2017-05-16 Neurovive Pharmaceutical Ab composto, composição farmacêutica, métodos para tratamento de infecções virais e de distúrbios inflamatórios, e, processo para produzir uma sangliferrina mutassintética
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
WO2012145426A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
PT2859009T (pt) * 2012-06-08 2018-01-18 Gilead Sciences Inc Inibidores macrocíclicos dos vírus flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
EA026235B1 (ru) * 2012-06-08 2017-03-31 Джилид Сайэнс, Инк. Макроциклические ингибиторы вирусов flaviviridae

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
CA2079912C (en) 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
GB9318612D0 (en) 1993-09-08 1993-10-27 Sandoz Ltd An assay
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
EP1012180B1 (de) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
RU2180862C2 (ru) * 1999-11-30 2002-03-27 Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН Способ лечения хронических вирусных гепатитов
ES2267722T3 (es) * 2000-03-02 2007-03-16 Sang Geon Kim Composicion farmaceutica para el tratamiento y prevencion de la fibrosis y cirrosis hepatica.
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
CN100490818C (zh) 2000-05-26 2009-05-27 诺瓦蒂斯有限公司 β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SK742003A3 (en) 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2001255070A1 (en) 2000-08-28 2002-03-13 Jin-Sub Kim Generator of two-wheeled vehicle and lighting system thereby
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
BRPI0515494A (pt) * 2004-10-01 2008-07-29 Debiopharm Sa uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
CA2611151A1 (en) 2006-12-28
MX2007016068A (es) 2008-03-10
CN101242842A (zh) 2008-08-13
ECSP078029A (es) 2008-01-23
AU2006259348A1 (en) 2006-12-28
BRPI0613142A2 (pt) 2010-12-21
AU2006259348B2 (en) 2010-07-22
PE20070118A1 (es) 2007-02-23
EP1893211B1 (de) 2011-09-14
GT200600262A (es) 2007-03-28
RU2427372C2 (ru) 2011-08-27
RU2008100587A (ru) 2009-07-27
TNSN07477A1 (en) 2009-03-17
EP1893211A1 (de) 2008-03-05
KR20080033274A (ko) 2008-04-16
TW200740438A (en) 2007-11-01
US20090221598A1 (en) 2009-09-03
WO2006138507A1 (en) 2006-12-28
ATE524183T1 (de) 2011-09-15
NO20080351L (no) 2008-03-14
JP2008546708A (ja) 2008-12-25
AR054778A1 (es) 2007-07-18
MA29600B1 (fr) 2008-07-01

Similar Documents

Publication Publication Date Title
ZA200710551B (en) Use of sanglifehrin in HCV
IL191072A0 (en) Therapeutic compositions and methods
ZA200800256B (en) Antiviral compounds and methods
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
GB0427145D0 (en) Compositions for use in surgery
GB0512940D0 (en) Compounds and their use
ZA200804299B (en) 3-amino-2-arylpropyl azaindoles and uses thereof
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1968526A4 (de) Schäumende dentalzusammensetzungen und verfahren
IL184062A0 (en) Visco-supplement composition and methods
GB0514891D0 (en) Improvements in and relating to implants
GB0520743D0 (en) Compounds and their use
GB0417359D0 (en) Improvements in compositions
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
DK2392335T3 (en) Use of 24-norUDCA
IL186307A0 (en) Human glp-1 mimetibodies, compositions, methods and uses
GB0501348D0 (en) Compositions and methods
ZA200706038B (en) Visco-supplement composition and methods
HK1115527A (en) Use of sanglifehrin in hcv
GB0405508D0 (en) Improvements in or relating to scalpels
GB0405507D0 (en) Improvements in or relating to scalpels
GB2432516B (en) Footstool
GB2418453B (en) Improvements in latches
GB2424794B (en) Improvements in the use of pre-configuration
GB0512528D0 (en) Boat chair